Geli's original full oral hepatitis C cure program was selected for the 2018 American Hepatology Annual Conference poster speech

November 6, 2018 / Meitong news agency / -- Geli Pharmaceutical Co., Ltd (Geli pharmaceutical 1672 HK), a biopharmaceutical company that is committed to solving the unmet medical needs in the three major fields of antiviral, cancer and fatty liver disease, and has entered the commercialization stage, today announced that the full oral hepatitis C cure plan II / III developed by the company Phase I clinical study has passed the evaluation of the Organizing Committee of the 69th annual meeting of the American Society for the study of liver diseases (AASLD), and has been selected as a "wall newspaper speech" Professor Wei Lai, the main researcher of the study and the people's Hospital of Peking University, will give an oral report on the spot at 2:00 p.m local time on November 12, 2012 This is also the first time that China's original DAA has made a report at the American annual meeting of liver diseases This study is a large-scale, multicenter, randomized, double-blind, placebo-controlled, phase II / III trial involving 42 centers in mainland China 424 newly treated adults with GT1 HCV infection were included in the study The main end point was to evaluate the efficacy and safety of all oral treatment based on ravidavir in the newly treated patients with non cirrhosis gene 1 HCV infection It was confirmed that the cure rate (svr12) was as high as 99% after the treatment of ravidavir combined with ritonavir, and the efficacy was not affected by the replacement of baseline NS5A drug resistance and had good tolerance Ravidavir is a new generation of Pan gene direct anti HCV drug developed by Geli for NS5A target It is used in combination with the first innovative anti HCV drug, gonovi ®, approved for market in early June 2018, to form the first all oral interferon free hepatitis C cure plan (RDV / DNV treatment plan) in China Wall newspaper speech: Title: efficiency and safety of all oral, 12 week ravidasvir plus ritonavir boosted danoprevir and ribavirin in treatment na.ve non cirrhotic HCV genotype 1 patients: results from a phase 2 / 3 clinical trial in China Reporter: Professor Wei Lai time: 2:00 p.m local time, November 12, U.S location: Moscone Center North / South Building, hall C source: Geli Pharmaceutical Co., Ltd